• EBITDA margin guidance: Following a 31.4% EBITDA margin and revenue of ₹8,217 crore in the June quarter, the company maintains long-term core EBITDA margin guidance of upward of 25% despite anticipated quarterly volatility.
• Complex portfolio pivot: R&D investments are focusing on complex generics, respiratory treatments, injectables, and biosimilars like Peg-GCSF and Ranibizumab, supported by streamlined biomarker-based regulatory pathways.
• M&A leverage capacity: With approximately ₹3,000 crore in cash remaining after acquiring VisuPharma, Lupin has the balance sheet capacity to leverage $1.5 billion to $2 billion for disciplined acquisitions across ophthalmology, respiratory, and orphan drug assets.
• GLP-1 segment strategy: Lupin currently holds the top market position for semaglutide in India and plans to introduce bofenglutide, a long-acting fortnightly formulation, leveraging its strong diabetes specialist network.
• Cost and competition headwinds: Near-term execution risks include rising ocean and air freight costs—which added $1.5 million to $2 million in expenses during the quarter—alongside upcoming exclusivity losses for Tolvaptan and heightened competition for generic Mirabegron.